Navigation Links
Pharmaceutical Institute Launches New E-Course Focused on Health Policy
Date:6/17/2009

RALEIGH, N.C., June 17 /PRNewswire/ -- Pharmaceutical Institute (PI), a leading provider of specialized training solutions for the pharmaceutical and biotech industry, today announced the release of a new e-course titled, Introduction to Health Policy. The course is the newest addition to the company's Managed Markets Excellence(TM) series. The new Introduction to Health Policy e-course provides a comprehensive overview of the challenges confronting the US healthcare system.

"As politicians and policy makers continue to debate options to reform our healthcare system, pharmaceutical and biotech companies are working to understand the potential effects of policy changes, both large and small," says Garry O'Grady, Senior Vice President of the Pharmaceutical Institute. "It is important for pharmaceutical and biotech companies to keep their teams abreast of these potential policy changes and to understand the possible implications to their business."

The Introduction to Health Policy e-course, developed in partnership with subject-matter experts from Campbell Alliance, provides team members with the background necessary to understand the potential policy changes facing the industry, as well as the impacts of these changes on the way companies develop, market, and sell their products. The 2-hour e-course consists of four comprehensive modules, providing team members with a solid foundation on current health policy issues, including

  • Health Policy Stakeholders -- This module provides an introduction to key players in the development of health policy, their roles, and the differing perspectives they "bring to the table." Team members will also become familiar with leaders spearheading current efforts to achieve health insurance reform.
  • US Health Coverage - A Current View -- As a necessary backdrop for understanding healthcare reform efforts, this module provides an overview of the existing health insurance landscape in the US. The roles played by both commercial health plans and the major government insurance programs are explored.
  • Health Reform Options -- For the first time in decades, major health insurance reform is at the top of the Capitol Hill agenda. This module clarifies the confusing array of reform options that are currently under consideration and explains the perspectives of advocates and opponents. Possible implications of change for the pharmaceutical and biotechnology sector are explored.
  • Hot Topics -- Health reform isn't the only front-burner health policy issue on Capitol Hill today. This module explores recent or proposed "movement" on five other pressing issues related to healthcare quality and cost, including Medicare Part D non-interference clause, comparative effectiveness research, drug reimportation, health information technology, and follow-on biologics. The discussion spotlights concerns that these issues have aroused in the pharmaceutical and biotechnology industry.

For more information on the Introduction to Health Policy e-course, please visit

http://www.pharmainstitute.com/training-solutions/managed-markets/health-policy/index.cfm

For more information on the Managed Markets Excellence(TM) e-course series, please visit

http://www.pharmainstitute.com/training-solutions/managed-markets/index.cfm

About the Pharmaceutical Institute

Pharmaceutical Institute is a leading provider of specialized training programs for the pharmaceutical and biotech industry. We partner with subject matter experts from our parent company, Campbell Alliance, to develop highly-impactful distance learning solutions for professionals within all major pharmaceutical company functions including Brand Management, Business Development, Clinical Development, Managed Markets, Medical Affairs, Sales, and Trade and Distribution. The Pharmaceutical Institute is based in Raleigh, N.C. For more information, please visit www.pharmainstitute.com.


'/>"/>
SOURCE Pharmaceutical Institute
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... ... Proove Biosciences, Inc. , the commercial and research leader in personalized ... The partnership is designed to advance research in pain genetics in an effort to ... the new agreement, researchers at Proove Biosciences are able to collaborate with Luda Diatechnko, ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research "Metabolomics Market - Global Industry ... 2024", the metabolomics market is anticipated to expand at ... reach USD 2,494.8 million by 2024. Metabolomics ... as metabolites, within cells, biofluids, tissues or organisms. Together, ...
(Date:5/3/2016)... , May 3, 2016 ... (Genomics, Drug Discovery, Gene Expression) Lab-on-a-chip (IVD ... (Academics Institutes, Diagnostics Centers), Fabrication Technology (Microarrays, ... MarketsandMarkets, the market is expected to reach ... 7.63 Billion in 2015, growing at a ...
(Date:5/3/2016)... Boston, Massachusetts (PRWEB) , ... May 03, 2016 ... ... communities will gather at Boston CEO 2016 on May 31st and June 1st ... off-the-record networking forum for leading executives in the life sciences, offering exclusive access ...
Breaking Biology Technology:
(Date:3/10/2016)... 10, 2016   Unisys Corporation (NYSE: UIS ... (CBP) is testing its biometric identity solution at the ... to help identify certain non-U.S. citizens leaving the country. ... designed to help determine the efficiency and accuracy of using ... and will run until May 2016. --> ...
(Date:3/9/2016)... HAMBURG, Germany , March 9, 2016 ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ... West African country,s government identified that more than 23,000 ... recorded name or had been receiving their salary unlawfully. ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):